In vivo, individual deletion of Crebbp or Kmt2d in the GC was insufficient alone to drive full malignant transformation but accelerated the development of FL/DLBCL-like lymphomas in a Bcl2-transgenic background, consistent with a haploinsufficient tumor suppressor role (14, , –17). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.